Ifebemtinib

Ifebemtinib (also known as IN10018, ifebe, BI853520) is  an orally administered, highly potent and selective small molecular inhibitor of the focal adhesion kinase (FAK). InxMed translational research has demonstrated the essential functions of FAK in tumor defense. 

Learn more  >>

OMTX705

OMTX705 is an ADC formed by a new humanized anti-FAP mAb that has been conjugated to a novel cytolysin, TAM470, a synthetic microtubule inhibitor from the tubulysin family. IN30705 is designed to target FAP-expressing Cancer Associated Fibroblasts (CAFs) in tumor microenvironment. 

Learn more  >>

NEXT GENERATION ADC

InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing.  

Learn more  >>